AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23475451 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (N=105) providing on‐site infectious disease education, screening of risk level, pretest counseling, testing for HIV and hepatitis B and C, vaccination for hepatitis A and B, and personalized risk‐reduction counseling
Number of subjects: 202
Study 23475451 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 202
Study 21176079 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy (81 mg, intravesically instilled once weekly for 6 weeks as induction therapy, followed by three once-weekly instillations at 3, 6, 12 and 18 months)
Number of subjects: 116
Study 21176079 — intervention group
Group type: COMPARATOR
Intervention: BCG non-maintenance therapy (81 mg, intravesically instilled once weekly for 6 weeks)
Number of subjects: 116
Study 21176079 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin therapy (40 mg, intravesically instilled nine times)
Number of subjects: 116
Study 19958865 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive filling pattern in patients with atrial fibrillation
Number of subjects: 880
Study 19958865 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive filling pattern in patients with sinus rhythm
Number of subjects: 880
Study 19958865 — intervention group
Group type: COMPARATOR
Intervention: Patients in sinus rhythm
Number of subjects: 880
Study 17413839 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones
Number of subjects: 203
Study 17413839 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones
Number of subjects: 203
Study 17413839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg isoflavones)
Number of subjects: 203
Study 15225827 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 0
Study 15225827 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0
Study 15225827 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11407675 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiband ligation
Number of subjects: 0
Study 11407675 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy combined with band ligation
Number of subjects: 0
Study 9644639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 205
Study 9644639 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 205
Study 7944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid release theophylline
Number of subjects: 14
Study 7944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline
Number of subjects: 14
Study 7944005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3266333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine therapy
Number of subjects: 54
Study 3266333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bromocriptine)
Number of subjects: 54
Study 30281551 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient screening activities
Number of subjects: 8
Study 30281551 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient contact activities
Number of subjects: 8
Study 30281551 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing procedures
Number of subjects: 8
Study 30281551 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician contact activities
Number of subjects: 8
Study 30281551 — intervention group
Group type: EXPERIMENTAL
Intervention: Other activities
Number of subjects: 8
Study 28399844 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple marker screening followed by patient and provider education
Number of subjects: 1819
Study 28399844 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple marker screening, education, and clinical pharmacist-led CKD and BP management program
Number of subjects: 1819
Study 28399844 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1819
Study 25631707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group setting intervention (n=77)
Number of subjects: 425
Study 25631707 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual setting intervention (n=78)
Number of subjects: 425
Study 25631707 — intervention group
Group type: COMPARATOR
Intervention: Stress management education (SME)
Number of subjects: 425
Study 23395189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 134
Study 21689775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio) plus transdermal tulobuterol (Tulo) 18 μg once daily plus 2 mg once daily for 4 weeks
Number of subjects: 16
Study 21689775 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (Tio) 18 μg once daily for 4 weeks
Number of subjects: 16
Study 21689775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio) plus transdermal tulobuterol (Tulo)
Number of subjects: 16
Study 21689775 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (Tio)
Number of subjects: 16
Study 19381345 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical efficiency maximization method for covariate adjustment
Number of subjects: 0
Study 19381345 — intervention group
Group type: COMPARATOR
Intervention: Standard locally efficient estimators
Number of subjects: 0
Study 16987311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P) programs
Number of subjects: 798
Study 16987311 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-item survey measuring key features of P4P programs
Number of subjects: 798
Study 12691930 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapreotide
Number of subjects: 275
Study 12691930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 11467343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) infusion of α-Lipoic acid (LA)
Number of subjects: 0
Study 11467343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of α-Lipoic acid (LA)
Number of subjects: 0
Study 9663825 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 (5 mg/kg, single intravenous infusion)
Number of subjects: 15
Study 8245892 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of acyclovir twice daily
Number of subjects: 1146
Study 8245892 — intervention group
Group type: COMPARATOR
Intervention: Episodic treatment (ES)
Number of subjects: 1146
Study 8245892 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label acyclovir suppressive therapy
Number of subjects: 1146
Study 3516408 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray, dosage 1 mg
Number of subjects: 25
Study 3516408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29470365 — intervention group
Group type: EXPERIMENTAL
Intervention: Chain BP
Number of subjects: 13
Study 29470365 — intervention group
Group type: COMPARATOR
Intervention: Plate BP
Number of subjects: 13
Study 29509516 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg
Number of subjects: 128
Study 29509516 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 128
Study 29509516 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 128
Study 29509516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 27898164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg IV)
Number of subjects: 138
Study 27898164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 138
Study 25842461 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP combined with prescription-tray application of 1.7% hydrogen peroxide gel and doxycycline for 2 weeks
Number of subjects: 61
Study 25842461 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP combined with prescription-tray application of 1.7% hydrogen peroxide gel
Number of subjects: 61
Study 25842461 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 61
Study 22678317 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILS‐C)
Number of subjects: 65
Study 22678317 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 65
Study 20124186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg/d (1,125 mg loading dose, day 1)
Number of subjects: 266
Study 20124186 — intervention group
Group type: COMPARATOR
Intervention: Lomustine (100 to 130 mg/m2, day 1)
Number of subjects: 266
Study 20124186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Number of subjects: 266
Study 20124186 — intervention group
Group type: COMPARATOR
Intervention: Lomustine
Number of subjects: 266
Study 19102734 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 555
Study 19102734 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 555
Study 16186525 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic stockings + Intermittent pneumatic compression (IPC)
Number of subjects: 151
Study 16186525 — intervention group
Group type: COMPARATOR
Intervention: Elastic stockings (ES) alone
Number of subjects: 151
Study 12444284 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal transurethral resection of the prostate followed by bladder neck incision
Number of subjects: 40
Study 12444284 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 40
Study 10081852 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (40 mg)
Number of subjects: 261
Study 10081852 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (120 mg, Danish strain 1331)
Number of subjects: 261
Study 10081852 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line BCG
Number of subjects: 261
Study 10081852 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line Mitomycin C
Number of subjects: 261
Study 10081852 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 261
Study 10081852 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 261
Study 7769899 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 1680
Study 7769899 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 1680
Study 7769899 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 1680
Study 2349137 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 25 mg
Number of subjects: 7
Study 2349137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 665568 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.2 g of hemicellulose supplement per subject per day
Number of subjects: 19
Study 665568 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.2 g of cellulose supplement per subject per day
Number of subjects: 19
Study 665568 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.2 g of pectin supplement per subject per day
Number of subjects: 19
Study 665568 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.2 g of pectin plus 1.3 g of zinc
Number of subjects: 19
Study 665568 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.2 g of pectin plus 9.3 g of zinc
Number of subjects: 19
Study 665568 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2 g of pectin plus 1.3 g of zinc
Number of subjects: 19
Study 665568 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2 g of pectin plus 9.3 g of zinc
Number of subjects: 19
Study 31324132 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided detection software
Number of subjects: 120
Study 31845226 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Acupuncture (DA)
Number of subjects: 30
Study 31845226 — intervention group
Group type: COMPARATOR
Intervention: Shallow Acupuncture (SA)
Number of subjects: 30
Study 27853058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 917
Study 27853058 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 917
Study 27853058 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 917
Study 27853058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 917
Study 25060913 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition (n=16)
Number of subjects: 26
Study 24050737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 33
Study 24050737 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2 mg)
Number of subjects: 33
Study 20878653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (5 mL of liquid fibrin sealant sprayed before drains insertion)
Number of subjects: 30
Study 20878653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 30
Study 19338151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginaton (0.5 mg/kg)
Number of subjects: 20
Study 19338151 — intervention group
Group type: COMPARATOR
Intervention: Control (routine CPB and cold St. Thomas' cardioplegia perfusion)
Number of subjects: 20
Study 17403437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring pessary
Number of subjects: 134
Study 17403437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gellhorn pessary
Number of subjects: 134
Study 15488063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiff paediatric laryngoscope blade
Number of subjects: 78
Study 15488063 — intervention group
Group type: COMPARATOR
Intervention: Miller laryngoscope blade
Number of subjects: 78
Study 15488063 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope blade
Number of subjects: 78
Study 12603357 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia software package 'All About Nocturnal Enuresis'
Number of subjects: 270
Study 12603357 — intervention group
Group type: COMPARATOR
Intervention: Written leaflets containing the same information
Number of subjects: 270
Study 10201475 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg/h continuous infusion after an initial 100-microg bolus)
Number of subjects: 25
Study 10201475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7781346 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg methylprednisolone
Number of subjects: 150
Study 7781346 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg methylprednisolone
Number of subjects: 150
Study 2150527 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg GBR 12909
Number of subjects: 8
Study 2150527 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg GBR 12909
Number of subjects: 8
Study 2150527 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg GBR 12909
Number of subjects: 8
Study 2150527 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg GBR 12909
Number of subjects: 8
Study 2150527 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg GBR 12909
Number of subjects: 8
Study 2150527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2150527 — intervention group
Group type: EXPERIMENTAL
Intervention: GBR 12909 (various doses)
Number of subjects: 8
Study 2150527 — intervention group
Group type: EXPERIMENTAL
Intervention: GBR 12909
Number of subjects: 8
Study 376079 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompton mixture (containing morphine, cocaine, ethyl alcohol, syrup BP, and chloroform water) administered orally
Number of subjects: 0
Study 376079 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone in a flavoured aqueous solution administered orally
Number of subjects: 0
Study 31967283 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐point group (local anesthetic at 'anesthesia point', alcohol at 'lesion point')
Number of subjects: 30
Study 31967283 — intervention group
Group type: COMPARATOR
Intervention: Single‐point group (alcohol and local anesthetic at the same point)
Number of subjects: 30
Study 31967283 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐point group
Number of subjects: 30
Study 31525829 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD) with Compression Bandage (CB)
Number of subjects: 46
Study 31525829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression (IPC) with Compression Bandage (CB)
Number of subjects: 46
Study 27384328 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV
Number of subjects: 28
Study 26607745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronator quadratus (PQ) repair
Number of subjects: 60
Study 26607745 — intervention group
Group type: COMPARATOR
Intervention: No repair (Control)
Number of subjects: 60
Study 23812862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous interferon (IFN) administered during the anhepatic phase of liver transplantation, along with weight-based ribavirin and subcutaneous IFN at time of incision.
Number of subjects: 15
Study 23812862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intravenous interferon).
Number of subjects: 15
Study 20932360 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care cognitive behaviour therapy (CBT) - 10 sessions
Number of subjects: 133
Study 20932360 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care cognitive behaviour therapy (CBT) - 5 additional sessions (second phase)
Number of subjects: 133
Study 20932360 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care cognitive behaviour therapy (CBT) - 5 additional sessions (third phase)
Number of subjects: 133
Study 20932360 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care cognitive behaviour therapy (CBT)
Number of subjects: 133
Study 19031371 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized target heart rate calculated corresponding to an intensity of 60% to 80% of calculated VO(2)max (97 to 137 beats per minute)
Number of subjects: 61
Study 17319037 — intervention group
Group type: COMPARATOR
Intervention: Topical clobetasol propionate 0.05% cream
Number of subjects: 36
Study 17319037 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene 0.1% cream
Number of subjects: 36
Study 15525784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (0.26 mA) applied during SWS-rich sleep for 30 minutes
Number of subjects: 0
Study 15525784 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study 15525784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS during wake retention interval
Number of subjects: 0
Study 15525784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 11251629 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 48968C (100 mg orally once daily for 9 days)
Number of subjects: 12
Study 11251629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10050402 — intervention group
Group type: EXPERIMENTAL
Intervention: nonspecific combined detoxication
Number of subjects: 176
Study 7983293 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 94
Study 7983293 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 94
Study 7983293 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous episodes of depression
Number of subjects: 94
Study 7983293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 94
Study 7983293 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period
Number of subjects: 94
Study 30777117 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing (XBJ) injection
Number of subjects: 300
Study 30777117 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl injection (placebo control)
Number of subjects: 300
Study 29078800 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programme
Number of subjects: 0
Study 29078800 — intervention group
Group type: COMPARATOR
Intervention: Control group (not informed)
Number of subjects: 0
Study 26175332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (EPA)
Number of subjects: 290
Study 26175332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 25607558 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine emulsion (CsAE)
Number of subjects: 24
Study 25607558 — intervention group
Group type: COMPARATOR
Intervention: Emulsion (vehicle)
Number of subjects: 24
Study 25607558 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated nails
Number of subjects: 24
Study 21196426 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking outdoors near roadways
Number of subjects: 0
Study 21196426 — intervention group
Group type: COMPARATOR
Intervention: Walking indoors
Number of subjects: 0
Study 21196426 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 gene deletion
Number of subjects: 0
Study 19561372 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cycle ergometry
Number of subjects: 17
Study 19561372 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength cycle ergometry
Number of subjects: 17
Study 19561372 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 16941406 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Aspirin (ASA) once daily
Number of subjects: 250
Study 16941406 — intervention group
Group type: COMPARATOR
Intervention: 75 mg Clopidogrel once daily
Number of subjects: 250
Study 15385014 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 1 mg x kg(‐1) (group K)
Number of subjects: 44
Study 15385014 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 0.5 mg x kg(‐1) plus clonidine 1 microg x kg(‐1) (group KC)
Number of subjects: 44
Study 11222185 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL/kg of low osmolality contrast medium
Number of subjects: 457
Study 11222185 — intervention group
Group type: COMPARATOR
Intervention: 150 mL of low osmolality contrast medium
Number of subjects: 457
Study 11222185 — intervention group
Group type: COMPARATOR
Intervention: 100 mL of low osmolality contrast medium
Number of subjects: 457
Study 9444494 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine and adjunct bright-light therapy
Number of subjects: 28
Study 9444494 — intervention group
Group type: COMPARATOR
Intervention: Trimipramine monotherapy
Number of subjects: 28